-
Medical Health Monthly Report The amount of financing increased by 80% month-on-month, and these five major projects were the most eye-catching
Time of Update: 2022-12-30
Figure 2: Number and amount of funding rounds this month Source: Firestone Creation Industry Data Center【Geographical distribution of financing】This month's financing projects were mainly distributed in Guangdong Province (26 cases) and Jiangsu Province (21 cases).
-
Decoding the Chinese Digital Therapeutics (DTx) Market
Time of Update: 2022-12-30
High quality, accessibility, cost control, unbalanced medical resources, differentiated patient needs, and uneven patient management efficiencyFor pharmaceutical companies, how to carry out digital layout as soon as possible to obtain "first-mover advantages", accurate insight into the successful experience and trial and error lessons of the market to "avoid detours" is crucial, IQVIA is willing to work with all parties to grasp the opportunities of China's digital therapeutics market, explore the path of commercialization, and solve problems at all stages.
-
$4 billion down payment! Takeda introduces TYK2 inhibitors
Time of Update: 2022-12-30
Original: _mstmutation="1" _msthash="220727" _msttexthash="19154421"> On December 13, Takeda announced that it would acquire NDI-034858 from Nimbus Therapeutics.
Original: _mstmutation="1" _msthash="220727" _msttexthash="19154421"> On December 13, Takeda announced that it would acquire NDI-034858 from Nimbus Therapeutics.
-
I, the medical representative of the original research drug, helped competitors sell generic drugs after collective procurement
Time of Update: 2022-12-30
”Helpless move: help compete to sell medicineHelpless move: help compete to sell medicineIn order not to stop the drug, Zhang Yu and his colleagues can only promote the winning generic drug to doctors to ensure that the hospital can complete the centralized procurement quota in advance every month.
-
APIs rise once an hour, and the company's 24-hour production is not enough to sell, what is the solution to the dilemma of drug discontinuation under the new crown? Industry prediction: we have to wait half a month!
Time of Update: 2022-12-30
After the epidemic was released, Beijingers were busy writing jokes that were false, and buying medicine everywhere was the truth. After the epidemic was released, Beijingers were busy writing jokes t
-
Pfizer and Amgen win annual TOP mergers and acquisitions! There is no big explosion in Biotech mergers and acquisitions in 2022, and the wave of mergers and acquisitions in China is far from coming
Time of Update: 2022-12-30
Biotech companies have become accustomed to getting funding from venture capital and IPO channels, which makes them less receptive to acquisitions and forces potential acquirers to provide more money to lock in deals.
-
9 guidelines to avoid the pit of new crown medication, taking the wrong medicine is not a joke
Time of Update: 2022-12-30
After the optimization of the epidemic prevention and control policy, residents infected with the new crown virus can choose to stay at home, and many people have purchased a variety of medicines acc
-
Academician Gao Fu's latest voice: You can't treat hospitals as vegetable markets! The new crown towards "Class B and B pipe" is the general direction!
Time of Update: 2022-12-30
But there is a basic concept, everyone must know, Omicron is still a new crown virus, is a wolf to eat sheep, this is a big ecology, without mutton, how do wolves live?When the virus spreads in the population, it is likely to cause severe illness or death in people, resulting in large group infections.
-
For the treatment of psoriasis, Boehringer Ingelheim IL-36R monoclonal antibody was approved in China
Time of Update: 2022-12-30
9% of patients, clearance or near-clearance of skin symptoms was achieved with pesolimab for 1 weekEffisayilTM, Director of the Department of Dermatology, Huashan Hospital Affiliated to Fudan University Professor Xu Jinhua, China Chief Investigator of Phase 2 Clinical Trial 1, said: "As the first monoclonal antibody of its kind to block the IL-36 receptor, the approval of San Lizo is of breakthrough significance in the development of GPP diagnosis and treatment in China and even the world.
-
BI rare skin disease drug San Lizo China approved; China Pharmaceutical will be responsible for the import and distribution of Paxlovid in Chinese mainland
Time of Update: 2022-12-30
Pharmacis SelectionPharmacis SelectionBoehringer Ingelheim rare dermatology drug IL-36R monoclonal antibody San Ligzo China approvedBoehringer Ingelheim rare dermatology drug IL-36R monoclonal antibody San Ligzo China approvedBoehringer Ingelheim today announced that its application for the marketing of its innovative drug for rare skin diseases, San Lizo (pesolimab injection), has been approved by the State Food and Drug Administration for the treatment of generalized pustular psoriasis (GPP) in adults.
-
Continuing to divest "non-core" businesses, Novartis sold a number of products
Time of Update: 2022-12-30
GBI Recently, Harrow Health, an ophthalmic pharmaceutical company, announced that it will obtain exclusive commercialization rights for 5 ophthalmic products owned by Swiss pharmaceutical company Novartis.
GBI Recently, Harrow Health, an ophthalmic pharmaceutical company, announced that it will obtain exclusive commercialization rights for 5 ophthalmic products owned by Swiss pharmaceutical company Novartis.
-
Rico Bio: ReCOV beats Pfizer mRNA vaccine head-to-head
Time of Update: 2022-12-30
Rico Bio's ReCOV effectiveness has significant advantages, and both the prototype strain and the Omicron variant can induce durable neutralizing antibodies, and the titer is significantly higher than that of the Pfizer mRNA vaccine.
-
Cut core executives and save three or five pounds of rations American oncology precision medicine company in the cold winter
Time of Update: 2022-12-30
After all, due to many factors such as the immaturity of the market, the great challenge of commercialization, and the overly "involution", it is not realistic for enterprises to rely on the tumor precision medicine business to increase revenue and profits.
-
Heavy! The outline of the Chinese Pharmacopoeia (2025 edition) was officially released
Time of Update: 2022-12-30
(6) Accelerate the informatization of drug standards (i) Appropriately increase the scope of pharmacopoeia varieties, adhere to the principles of common clinical use, precise efficacy, safe use, mature technology and controllable quality, and continue to expand the coverage of catalogue varieties in combination with the adjustment of the national basic drug list and the national basic medical insurance drug list, and promptly include innovative drugs.
-
Inventory of Top5 License out of innovative oncology drugs in the past two years
Time of Update: 2022-12-30
TOP4：PD-1 TOP4：PD-1On January 13, 2021, BeiGene announced a collaboration and licensing agreement with Novartis for the development, manufacturing and commercialization of its self-developed anti-PD-1 antibody drug Bezean (tislelizumab) in multiple countries, with an initial payment of up to US$650 million and a total transaction value of more than US$2.
-
Inventory: Top 5 M&A transactions in the biomedical industry in 2022
Time of Update: 2022-12-30
7 billion core product Tavneos (avacopan) Information Reference: Information Reference: The official website of each company The official website of each company On June 3, Best-Myer Squibb (BMS) announced the acquisition of clinical-stage oncology biopharmaceutical company Turning for $76 per share (totaling $4.
-
FDA Releases Draft Guidelines for Organizing Uncertain Cancer Drugs
Time of Update: 2022-12-04
Original English link: _mstmutation="1" _msthash="220727" _msttexthash="1532089"> In 2017, Merck's PD-1 inhibitor pembrolizumab was approved for the treatment of microsatellite instable tumors; In 2018, Eli Lilly's TRK inhibitor larotrectinib was approved for the treatment of NTRK fusion tumors.
-
AstraZeneca announced that innovative drugs for the treatment of uremia and other drugs have been launched in China
Time of Update: 2022-12-04
【Pharmaceutical Network Product Information】 Due to the complexity of the environment, the diet structure in the society and other factors, the number of uremia is rising, and it is showing a younger
-
Under the transformation of the pharmaceutical innovation market, biotech companies are actively "protecting the cold"
Time of Update: 2022-12-04
【Pharmaceutical Network Industry News】Recently, it has been reported that CStone Pharmaceutical's Suzhou Industrialization Base has suspended production and other related work for production services
-
The pharmaceutical industry is active in investment and financing, and these fields are attracting attention
Time of Update: 2022-12-04
Therefore, the entry of a large amount of capital will undoubtedly promote the acceleration of high-quality innovation and development of the biomedical industry.
Therefore, the entry of a large amount of capital will undoubtedly promote the acceleration of high-quality innovation and development of the biomedical industry.
